Daiichi Sankyo To Be Engaged In Ranbaxy’s Problems With U.S. FDA
This article was originally published in PharmAsia News
Executive SummaryDaiichi Sankyo plans to come to the aid of its recently acquired Ranbaxy Laboratories as the Indian drug maker attempts to handle accusations by U.S. FDA. Daiichi Sankyo President Takashi Shoda said his company would be actively engaged in the dealings between the two parties. The FDA blackballed two Ranbaxy plants earlier this year on grounds the drug maker submitted falsified data. Shoda said Daiichi is completing plans to address the problems cited by the FDA. (Click here for more - a subscription may be required
You may also be interested in...
Analyzing Quality Data Is Essential. Here’s What One Expert Says Your Firm Should Do To Stay In FDA’s Good Graces
Device makers should make sure they have adequate resources to analyze quality data they take in so they can prevent the recurrence of nonconforming products, processes and procedures. That’s just one nugget of advice from former FDA investigations branch director Ricki Chase, who explains why collecting and properly handling such data is critical to complying with agency expectations in this Medtech Insight Q&A interview.
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.